Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK of YHP1604 vs Telmisartan/Amlodipine + Rosuvastatin in Healthy Volunteers
NCT03116516Phase 1Completed
- Sponsor
- Yuhan
- Start
- Apr 2017
- Primary completion
- May 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of telmisartan + amlodipine + rosuvastatin in hypertension (HTN) and hyperlipidemia (2 arms), sponsored by Yuhan. Primary endpoints: Maximum Plasma Concentration and Area Under the Curve to the Last Measurable Concentration. Started Apr 2017; status: completed.
02
Drugs
telmisartan + amlodipine + rosuvastatin
03
Conditions
hypertension (HTN)hyperlipidemia
Beyond the preview
Go deeper on NCT03116516.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03116516.